Groundbreaking AI-Powered Prostate Cancer Treatment Optimization Tool Now Available at Associated Medical Professionals of NY

Associated Medical Professionals (A.M.P.) announced today the availability of the ArteraAI Prostate Test, an AI-powered risk stratification tool to help personalize and optimize treatments for patients with localized prostate cancer. Dr. Steven E. Finkelstein, National Director of the Center of Advanced Radiation Excellence (CARE) for U.S. Urology Partners and Director Radiation Oncology Research, helped in the development of the tool and was instrumental in its approval process.

“We were excited to be the first in New York to order the ArteraAI Prostate Test for our patients with prostate cancer. Cancer is a scary diagnosis for any patient, but with this new test, we can personalize care and help ensure that the treatments we prescribe will lead to the best outcomes,” said Dr. Steven E. Finkelstein. “The low cost and fast turnaround of the test make it much more accessible for patients while providing physicians with advanced information to identify optimal treatment plans.”

Prostate cancer is the second-leading cause of cancer death in American men, behind only lung cancer. Prostate cancer is a serious disease, but most men diagnosed with prostate cancer do not die from it. More than 3.5 million men in the United States who have been diagnosed with prostate cancer are still alive today, according to the American Cancer Society. Because of the variability in prostate cancer aggressiveness, a major challenge facing clinicians and patients is determining the right treatment options, as both under- and over-treatment can be an issue.

The ArteraAI Prostate Test is the only test in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. The ArteraAI Prostate Test can increase patients’ confidence by offering more clarity around whether they will benefit from a specific treatment course.

Dr. Christopher M. Pieczonka, CEO of Associated Medical Professionals of NY,  stated, “The use of multimodal artificial intelligence (MMAI – Artera) is a game changer for New York State patients. This is the only test that has prostate cancer specific mortality as a prognostic endpoint in localized prostate cancer, which enables us to identify the most beneficial treatment plans and provide the highest level of care to our patients.”

Artera’s multimodal artificial intelligence biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular prostate cancer therapy and has been validated using many Phase 3 randomized trials.

About Associated Medical Professionals of NY (A.M.P.)

Associated Medical Professionals of New York (A.M.P.) is a medical practice based in Syracuse serving the Central New York region. Established in 2008, A.M.P. has grown to become one of the largest groups of its kind in the area with nine offices and services at 13 hospitals. As a pivotal point of care in each community, A.M.P. is able to provide continuity of care for a vast population of patients. A.M.P. maintains a robust suite of services, including advanced urological care, robotic surgery, cancer care, radiation oncology,  interventional radiology, pathology, lithotripsy, imaging and clinical research. For more information about A.M.P., visit www.ampofny.com.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports five affiliated groups comprising over 180 providers across practices located in Florida, Indiana, Massachusetts, New York and Ohio. For more information, please visit www.us-uro.com.

About Artera

Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test. Artera’s laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera’s laboratory in Jacksonville, Florida, and can be ordered online at www.artera.ai.

Leading Radiation Oncologist Dr. Steven E. Finkelstein Joins Associated Medical Professionals of NY

Associated Medical Professionals of NY (A.M.P.) is pleased to announce that internationally recognized radiation oncology physician, researcher and thought leader Steven E. Finkelstein, M.D., DABR, FACRO, has joined its care team as Director of the Center of Advanced Radiation Excellence (CARE) and Director of Radiation Oncology Research.

Associated Medical Professionals of NY spans 18 locations in Central New York, including nine offices and nine hospitals. A.M.P. Radiation Oncology is the region’s leading provider of comprehensive cancer care services, providing the most advanced, effective treatments available for urological and other types of cancers. A.M.P. is an affiliate of U.S. Urology Partners, one of the largest independent providers of urological and specialty related services in the nation, which is backed by NMS Capital.

Dr. Finkelstein has treated thousands of patients with prostate cancer and genitourinary malignancies, been principal investigator for groundbreaking clinical trials, and continues contributing to prestigious scientific journals with over 11,000 literature citations with an H-Index of 42. Additionally, he is renowned in bladder, kidney and testicular cancer as well as lung, breast and skin cancers which he will also treat at A.M.P. Dr. Finkelstein is passionate about leadership in organized medicine and is a strong advocate for physicians and the patients they serve. He is a graduate of the University of Michigan, where he completed his medical degree, and spent his residency at Moffitt Cancer Center and fellowship at the National Cancer Institute, National Institutes of Health. Dr. Finkelstein has been recognized as a Castle Connolly Top Doctor for five years in a row.

Corina Tracy, Chief Executive Officer of U.S. Urology Partners, stated, “Dr. Steven Finkelstein’s extensive experience in radiation oncology care and his leadership in the medical field will be a tremendous asset to U.S. Urology Partners, Associated Medical Professionals of NY and most importantly to individuals receiving cancer care in the Central New York region. Dr. Finkelstein’s dedication will further our mission to provide the best treatment available to our patients in the most compassionate way utilizing the most advanced, proven technology for every person we are privileged to serve.”

Christopher M. Pieczonka, M.D., Chief Executive Officer of Associated Medical Professionals of NY and Corporate Director of Clinical Research of U.S. Urology Partners, stated, “The Central New York community has long been the geographic heart of New York State and is on the cusp of a significant population influx from the construction and opening of Micron Technology Inc. We have recruited Dr. Steven Finkelstein for his prowess and expertise in providing cutting-edge clinical research in all aspects of radiation oncology to our patients. Currently Associated Medical Professionals is running over 30 active clinical trials, and we anticipate exponential growth with Dr Finkelstein’s expertise.”

Steven E. Finkelstein, M.D., DABR, FACRO, stated, “I am passionate about advancing patient care for all and committed to outstanding cancer care providing access to today’s leading-edge technologies and innovative treatment options. I am excited to join the team of Associated Medical Professionals of NY and look forward to helping patients in the community.”

To learn more about Dr. Finkelstein and A.M.P. or to schedule an appointment, please visit www.ampofny.com or call (315) 478-4185. Dr. Finkelstein will be based in the A.M.P. Syracuse office at 1226 East Water Street, Syracuse, NY 13210.

About U.S. Urology Partners

U.S. Urology Partners is one of the nation’s largest independent providers of urology and related specialty services, including general urology, surgical and robotic procedures, advanced cancer treatment and other ancillary services. The U.S. Urology Partners clinical network consists of more than 60 locations throughout the East Coast and Midwest, including affiliate practices Associated Medical Professionals of NY, Central Ohio Urology Group, Florida Urology Center, Greater Boston Urology and Urology of Indiana. U.S. Urology Partners was formed to support urology practices with an experienced team of healthcare executives and resources, and is backed by NMS Capital. The U.S. Urology Partners corporate office is in Nolensville, Tennessee, just outside of Nashville. For additional information about U.S. Urology Partners, visit www.us-uro.com.